Effects of inflammation on pharmacokinetics/pharmacodynamics: Increasing recognition of its contribution to variability in response

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 6, 2008, Pages 809-811

  Schmith, V D ^a   Foss, J F ^b  

^a GLAXOSMITHKLINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOCHROME P450 3A4; CYTOKINE; DRUG METABOLIZING ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; OROSOMUCOID;

ASTHMA; BLOOD BRAIN BARRIER; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG RESPONSE; DRUG TRANSPORT; ENTERITIS; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INJURY; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; MOLECULAR RECOGNITION; NEOPLASM; NONHUMAN; NOTE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SURGICAL TECHNIQUE; SYSTEMIC DISEASE; TREATMENT RESPONSE; UREMIA;

ANIMALS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 43949145953     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.62     Document Type: Note

References (14)

1. Petrovic, V., Teng, S. & Piquette-Miller, M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 7, 99-111 (2007).
2. Slaviero, K.A., Clarke, S.J. & Rivory, L.P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 4, 224-232 (2003).
3. Aitken, A.E., Richardson, T.A. & Morgan, E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46, 123-149 (2006).
4. Renton, K.W. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin. Drug Metab. Toxicol. 1, 629-640 (2005).
5. Robertson, G.R., Liddle, C. & Clarke, S.J. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin. Pharmacol. Ther. 83, 894-897 (2008).
6. Nolin, T.D., Naud, J., Leblond, F.A. & Pichette, V. The emerging impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83, 898-903 (2008).
7. Rao, R et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 72, 549-556 (2007).
8. Mayo, P.R., Skeith, K., Russell, A.S. & Jamali, F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol. 50, 605-613 (2000).
9. Kulmatycki, K.M., Abouchehade, K., Sattari, S. & Jamali, F. Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br. J. Pharmacol. 133, 286-294 (2001).
10. Guirguis, M.S. & Jamali, F. Disease-drug interaction: reduced response to propranolol despite increased concentration in the rat with inflammation. J. Pharm. Sci. 92, 1077-1084 (2003).
11. Clements, J.D. & Jamali, F. Pravastatin reverses the down-regulating effect of inflammation on β-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. Vasc. Pharmacol. 46, 52-59 (2007).
12. Piquette-Miller, M. & Jamali, F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvent arthritis. Drug Metab. Dispos. 23, 240-245 (1995).
13. Haas, C.E., Kaufman, D.C., Jones, C.E., Burnstein, A.H. & Reiss, W. Cytochrome P450 3A4 activity after surgical stress. Crit. Care Med. 31, 1338-1346 (2003).
14. Frye, R.F., Schneider, V.M., Frye, C.S. & Feldman, A.M.J. Plasma levels of TNF-α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J. Cardiac Failure 8, 315-319 (2002).